Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MPI | P34949 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631154 | 0.87 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL932621 | 0.85 | ATM (0.57) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL12947818 | 0.83 | KMT2A (0.69) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL14305323 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL21303901 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL18587751 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL10368830 | 0.83 | ATM (0.61) | ALDH1A1MAPTHSD17B10HRH3CD274 | |
| SCHEMBL1927765 | 0.83 | ALDH1A1 (0.70) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL3159167 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL12919996 | 0.83 | TP53 (0.53) | ALDH1A1MAPTHSD17B10HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4282206-A | 1-(4-AMINOPHENYL)-2-MORPHOLINYLETHANONE | WESTWOOD PHARMACEUTICALS INC. (US) | 1981-08-04 | — | — | US | claimed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20060110379-A1 | Linkage of agents using microparticles | PERICOR SCIENCE, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060104966-A1 | Transglutaminase linkage of agents to tissue | PERICOR SCIENCE, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-6958148-B1 | Linkage of agents to body tissue using microparticles and transglutaminase | PERICOR SCIENCE, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-6919076-B1 | Conjugates of agents and transglutaminase substrate linking molecules | PERICOR SCIENCE, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | disclosed |
| US-20030059471-A1 | Oral delivery formulation | COMPTON BRUCE JON (US) | 2003-03-27 | — | — | US | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
| US-6267957-B1 | Attaching agents to tissue with transglutaminase and a transglutaminase substrate | PERICOR SCIENCE, INC. | 2001-07-31 | — | — | US | disclosed |
| US-5236922-A | Method for treating depression using 1-(aminophenyl)-2-aminopropanone derivatives | LABORATOIRE L. LAFON (FR) | 1993-08-17 | — | — | US | disclosed |
| US-4980377-A | ANTIDEPRESSANTS, VASODILATION, IMMUNOSTIMULANTS | LABORATOIRE L. LAFON (FR) | 1990-12-25 | — | — | US | disclosed |
| US-4282206-A | 1-(4-AMINOPHENYL)-2-MORPHOLINYLETHANONE | WESTWOOD PHARMACEUTICALS INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | ALDH1A1 3369/4885MAPT 751/4885HSD17B10 2096/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | ALDH1A1 4117/4885MAPT 4825/4885HSD17B10 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.